Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen open-label extension after Lp(a)HORIZON
NL-OMON60026Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pelacarsen in atherosclerotic disease, sponsored by Novartis. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent serious adverse events and 4 more. Started May 2026; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on NL-OMON60026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60026.